mRNA-1073

· ModernaTX, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for mRNA-1073, covering 2024-02-28 to 2024-02-28. Get the full timeline:

Most recent: Clinical Trial Update: A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old [Phase 1, Phase 2]

See pricing